Get FREE U.S. Shipping on $75 Orders*

Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...

Abstract

BACKGROUND:

Lyme disease has a wide spectrum of clinical manifestations. Diagnosis is usually based on the clinical and serologic picture rather than on microbiological confirmation.

OBJECTIVE:

To examine the clinical presentation and treatment outcome of early
Lyme disease in patients with microbiologically confirmed erythema migrans.

DESIGN:

Observational cohort study.

SETTING:

31 university-based or clinician-practice sites in 10 endemic states.

PARTICIPANTS:

10 936 participants enrolled in a phase III trial of
Lyme disease vaccine; 118 participants had erythema migrans in which Borrelia burgdorferi was detected by culture or polymerase chain reaction.

MEASUREMENTS:

Clinical characteristics and treatment outcome were noted. Skin biopsies of erythema migrans were performed for culture and detection of B. burgdorferi by polymerase chain reaction; serologic responses were determined by Western blot.

RESULTS:

The 118 patients with microbiologically confirmed erythema migrans presented a median of 3 days after symptom onset. Early erythema migrans commonly had homogeneous or central redness rather than a peripheral erythema with partial central clearing. The most common associated symptoms were low-grade fever, headache, neck stiffness, arthralgia, myalgia, or fatigue. By convalescence, 65% of patients had positive IgM or IgG antibody responses to B. burgdorferi. Most patients responded promptly to antibiotic treatment.

CONCLUSIONS:

In major endemic areas in the United States,
Lyme disease commonly presents as erythema migrans with homogeneous or central redness and nonspecific flu-like symptoms. Clinical outcome is excellent if antibiotic therapy is administered soon after symptom onset.

Ann Intern Med. 2002 Mar 19;136(6):421-8. Clinical Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov’t

ProHealth CBD Store

 

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...



Leave a Reply